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Abstract Altered bone micro-architecture is an important
factor in accounting for fragility fractures. Until recently, it
has not been possible to gain information about skeletal
microstructure in a way that is clinically feasible. Bone
biopsy is essentially a research tool. High-resolution
peripheral Quantitative Computed Tomography, while
non-invasive, is available only sparsely throughout the
world. The trabecular bone score (TBS) is an imaging
technology adapted directly from the Dual Energy X-Ray
Absorptiometry (DXA) image of the lumbar spine. Thus, it
is potentially readily and widely available. In recent years,
a large number of studies have demonstrated that TBS is
significantly associated with direct measurements of bone
micro-architecture, predicts current and future fragility
fractures in primary osteoporosis, and may be a useful
adjunct to BMD for fracture detection and prediction. In
this review, we summarize its potential utility in secondary
causes of osteoporosis. In some situations, like glucocor-
ticoid-induced osteoporosis and in diabetes mellitus, the
TBS appears to out-perform DXA. It also has apparent
value in numerous other disorders associated with dimin-
ished bone health, including primary hyperparathyroidism,
androgen-deficiency, hormone-receptor positive breast
cancer treatment, chronic kidney disease, hemochromato-
sis, and autoimmune disorders like rheumatoid arthritis.
Further research is both needed and warranted to more
clearly establish the role of TBS in these and other disor-
ders that adversely affect bone.
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Introduction
Osteoporosis is the most common and costly of all bone
diseases [1–4], accounting for $34.8 billion in direct health
care costs per annum [5]. In the United States, it affects*10
million individuals age 50 and above, with an additional 34
million considered to be ‘‘at risk’’ [6]. Each year worldwide,
nine million new osteoporosis-related fractures are esti-
mated to occur [7], two million of which occur in the United
States alone [8]. Up to 10 % of women in their fifties have
already experienced an osteoporotic fracture [9]. Men are
also commonly affected [10–12]. The hip and the spine
fragility fracture, the most common sites, are associated with
increased morbidity and, in some cases, increased mortality
[13, 14]. These sobering demographic figures are destined to
increase with some experts predicting a doubling in fractures
over the next 40–50 years [7].
Osteoporosis has traditionally been categorized as pri-
mary and secondary. Primary osteoporosis refers to oste-
oporosis occurring in a postmenopausal woman and/or in
association with aging. Secondary osteoporosis is associ-
ated with a known underlying disease or medications.
Approximately one-third of postmenopausal women, and
one half of premenopausal women and men [5] suffer from
secondary osteoporosis. The most common secondary
causes of osteoporosis include long-term glucocorticoid
(GC) therapy, inflammatory arthritides (like rheumatoid
arthritis), hypogonadism in men, malabsorption syndromes,
and primary hyperparathyroidism [15].
The measurement of bone mineral density (BMD) by
dual energy X-ray absorptiometry (DXA) is the clinical
basis for the diagnosis of osteoporosis [16]. However,
while BMD is clearly one of the major determinants of
bone strength and fracture risk [17], the assessment of
fracture risk by BMD lacks sensitivity. In fact, more fra-
gility fractures occur in osteopenic individuals (T-score
between -2.5 and -1.0) than in subjects with osteoporosis
(T-score \ -2.5) [18]. It is clear that factors in addition to
BMD account for bone strength and fracture risk. They
include bone geometry, micro-architecture, as well as
micro-damage, mineralization, and turnover [19, 20]. With
specific reference to microstructure, standard DXA mea-
surements give no insight.
The gold standard for the direct assessment of bone
micro-architecture is histomorphometry of the transiliac
crest bone biopsy. However, the transiliac bone biopsy is
an invasive procedure and, moreover, does not necessarily
reflect microstructure at sites that fracture. A number of
non-invasive techniques have been developed recently to
assess skeletal micro-architecture. These techniques
include quantitative computed tomography (QCT) [21, 22],
high-resolution peripheral quantitative computed tomog-
raphy (HRpQCT) [23] and magnetic resonance imaging
(MRI) [24], all of which allow for either direct or indirect
measurement of bone micro-architecture. However,
assessing bone micro-architecture using QCT, HRpQCT or
MRI is costly and subjects the patient to another imaging
procedure. Alternatively, adaptation of X-ray-based ima-
ges, like plain radiographs, using gray-level textural fea-
tures has been explored utilizing fractal dimension and
Fourier analysis [25–30]. An ideal solution, in terms of
practicality, costs and risks, would be adaptation of DXA-
based images. In fact, DXA can now be used to identify
existing vertebral fractures [31–34], to evaluate hip
geometry and to estimate femoral strength [35–37].
Moreover, a new DXA-based measure that considers bone
mineral distribution in the proximal femur, instead of just
BMD, may be well suited to enhance standard densito-
metric evaluation as a predictor of hip fracture risk [38].
The latest development is the trabecular bone score (TBS),
a new gray-level textural metric that can be extracted from
the 2-dimensional lumbar spine DXA image to estimate
trabecular microstructure.
TBS is a texture parameter related to bone micro-
architecture that may provide skeletal information that is
not captured from the standard BMD measurement. Based
on experimental variograms of the projected DXA image,
TBS has the potential to discern differences in 3-dimen-
sional (3D) micro-architecture between 2-D DXA mea-
surements that are similar to each other [39, 40] (Fig. 1).
An elevated TBS value correlates with better skeletal
texture (a reflection of better micro-architecture); a low
TBS value correlates with weaker skeletal texture (a
reflection of degraded micro-architecture). The relationship
between TBS texture parameters and 3D micro-architec-
ture parameters has been documented by several ex vivo
studies that have reported significant correlations between
TBS and various micro-structural parameters of bone
assessed by micro-computed tomography [39, 41, 42].
From a practical standpoint, TBS can be applied retro-
spectively to previously acquired DXA images, without the
need for further imaging and, obviously, can be compared
directly with the same region of interest. Moreover, TBS
estimates generally are robust and independent from the
particular DXA instrument, as long as the device is prop-
erly calibrated [43]. This ability to assess TBS
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retrospectively using previously-obtained DXA images has
been instrumental in the collection of empirical data vali-
dating its use in clinical practice.
Clinically, TBS has been shown to predict current and
future fragility fractures in primary osteoporosis, to be a
helpful adjunct to BMD and clinical risk factors for frac-
ture detection and prediction, and for monitoring treatment
effect. A detailed review of the use of TBS for the man-
agement of primary osteoporosis has been published else-
where [40]. In addition, a number of studies have shown
that TBS has value in secondary causes of osteoporosis.
This is of interest, since in many of these conditions the
measurement of BMD by DXA lacks sensibility to predict
fracture risk. In cases of diabetes mellitus or long-term GC
exposure, for examples, the increase in fracture risk is not
governed by the expected relationship between BMD as
determined by DXA and fracture risk [44–49]. Similarly, in
asymptomatic primary hyperparathyroidism, trabecular
bone as evaluated by lumbar spine DXA, is relatively well
preserved [50]. This is in contrast to data from HRpQCT
studies that have shown deteriorated trabecular micro-
architecture, and epidemiological reports that provide evi-
dence for the increased fracture risk at both vertebral and
non-vertebral sites primary hyperparathyroidism [51–53].
While these unexpected findings between fracture risk and
BMD by DXA could be related to alterations in bone
microstructure in the other etiologies for osteoporosis,
current methods to assess bone microstructure are not
widely available [54]. To this end, TBS has the potential to
be used, in addition to BMD for fracture risk assessment in
secondary osteoporosis. The primary objective of this
report is to discuss the role of TBS in patients at risk for
and diagnosed with secondary osteoporosis.
TBS predictions of current and future fragility
fractures: primary osteoporosis
Most of the published research on TBS, to date, has been
conducted in patients with presumed primary osteoporosis,
or in whom risk factors for secondary osteoporosis were not
considered in the analysis. In such studies, TBS has been
shown to predict both current [55–64] and future/incident
[65–68] fragility fractures. Additional studies have addres-
sed the impact of efficacious therapies for osteoporosis on
TBS measurements. While TBS is usually maintained or
slightly improved in patients treated with bisphosphonates
[69, 70], preliminary data have shown a significant increase
in TBS in postmenopausal women treated with strontium
[71], teriparatide [72], or denosumab [73]. More specifically,
in terms of current fractures and within the context of cross-
sectional or retrospective studies, the TBS is consistently
lower in postmenopausal women with a past osteoporotic
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fracture than in women without fractures. Several of these
studies have shown that the TBS yields an incremental
increase in the odds ratio (OR) for spine or hip fractures
when combined with spine BMD [56–58, 65]. Moreover,
preliminary cross-sectional observations in men also suggest
that TBS is lower in men with vertebral fractures than in
their non-fractured counterparts [59]. With respect to pre-
dicting fragility fracture risk prospectively, the TBS, across
4 independent prospective studies in postmenopausal
women, has been shown to be at least as good as the BMD
in predicting hip fractures [65], vertebral fractures [65, 68],
and all fractures [65–67].
In terms of how the TBS responds to treatment, Krieg et al.
[69] investigated the effects of antiresorptive agents (86 %
bisphosphonates, 10 % raloxifene, and 4 % calcitonin) on the
TBS in women age 50 and older. Relative to baseline, there
was a significant improvement in BMD (?1.86 ± 1.8 % per
year), and a small increase in TBS (?0.2 ± 1.9 % per year) in
treated women over a mean follow-up of 3.7-years. Signifi-
cant reductions in mean BMD and the TBS were observed in
women treated with placebo. Similarly, in subjects treated
with zoledronic acid over a 3-year period, Popp et al. [70]
observed a significant increase in mean BMD, and a less-
pronounced but significant increase in TBS relative to base-
line. In 79 postmenopausal women with osteoporosis ran-
domized to receive either strontium 2 g/day or alendronate
70 mg/week, Hans et al. [71].noted that spine TBS signifi-
cantly increased by 2.3 and 3.1 % over one and 2 years,
respectively, in those on strontium, but not significantly (by
0.5 and 1.0 %, respectively) in those given alendronate. These
findings are in agreement with previously observations indi-
cating some benefit of strontium ranelate over alendronate in
terms of enhancing bone architecture [74]. Gu¨nther et al. [72],
in an open-labeled, multi-centre study, found that a 2-year
treatment with recombinant 1–34 human parathyroid hor-
mone (teriparatide) of postmenopausal women significantly
increased spine TBS by ?4.3 % and lumbar spine (LS) BMD
by ?7.6 %. At 2 years, there was no correlation between the
changes in BMD and TBS relative to baseline. Finally, in a
subset of 285 women from the FREEDOM trial of denosu-
mab, McClung et al. [73] observed significant increases in
both TBS (?2.4 %) and LS-BMD (?9.8 %) relative to
baseline in women treated with denosumab at 60 mg every
6 months for 3 years. In contrast, declines in both TBS and
BMD were noted among controls given placebo.
Trabecular bone score for secondary osteoporosis
As stated previously, secondary osteoporosis may arise
either as a result of the effects of underlying disease or
from medications (e.g., glucocorticoids). In fact, most of
the time, secondary osteoporosis results from the combi-
nations of risk factors and chronic diseases associated with
their treatment. The impact of these risk factors, treatments
and diseases on BMD is usually well documented, while
studies demonstrating their impact on bone micro-archi-
tecture are much less common. Nevertheless, it is likely
that bone micro-architecture plays an important role along
with BMD. For example, the increase in fracture risk
associated with glucocortoids (GC) occurs before major
bone loss can be measured by DXA [47]. This observation
could be related to GC-induced changes in bone micro-
architecture [75]. Most of the studies that have been
directed at TBS in the secondary osteoporoses are only
available as abstracts at this time. The following sections
summarize these data.
Glucocorticoid-induced (GC) osteoporosis
The therapeutic use of systemic GCs is one of the most
common secondary causes of osteoporosis, responsible for
an estimated 25 % of all cases [76]. Even low-doses of
prednisolone (2.5–7.5 mg/day) or the equivalent are asso-
ciated with an increase in the incidence of vertebral frac-
tures, with higher doses increasing that risk [47]. Up to
50 % of patients on long-term GC will sustain a fragility
fracture [77].
GCs increase the risk of fractures in several ways [77–
80], which include decreasing the production of estrogen
and testosterone, gonadotrophins, and reducing renal cal-
cium reabsorption and GI calcium absorption in the gas-
trointestinal tract. They also cause proximal muscle
wasting, which increases the risk of falls, especially among
the elderly and those with inflammatory arthritic conditions
like rheumatoid arthritis and systemic lupus erythematosis,
for whom steroids are typically used. However, the greatest
effects of GCs are on bone metabolism with the result
being reduced bone quantity and quality. Reduced bone
formation results from GC-induced inhibition of the dif-
ferentiation and replication of osteoblasts, and the induc-
tion of osteoblast apoptosis. In addition, GCs cause an
early transient increase in osteoclast lifespan, which
increases bone resorption. Further adverse effects of GC
that influence bone quality are increased osteocyte apop-
tosis and decreased skeletal angiogenesis, vascularity, and
blood flow within canaliculae [77, 79, 80]. Glucocorticoids
also augment the production of dickkopf-related protein 1
(DKK-1), an antagonist of the Wnt signaling pathway, and
suppresses the expression of runt-related transcription
factor-2 and bone morphogenetic protein, all of which
cause bone formation to decline [78].
Colson et al. [81] studied changes in TBS in 136 GC-
treated women, 45–80 years old, within a routine clinical
practice setting. All patients were treated with GC in a dose
equivalent to at least 5 mg of prednisolone daily for one or
more years. Glucocorticoid-treated patients demonstrated a
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significant 4.0 % decrease in TBS relative to aged-matched
healthy subjects (p \ 0.0001), while no significant change
in BMD was observed. Similar significant results were
observed among those on very low GC doses (\5 mg/day;
-3.5 % of TBS). Reduced TBS was evident irrespective of
the level of BMD, with a significant decline in TBS of 5.7
and 2.9 % in women with osteoporosis or osteopenia,
respectively. These findings were even more marked when
fracture status and number were taken into account. Among
those without a fracture, GCs induced a 3.4 % decline in
TBS. In those who sustained an osteoporosis-related frac-
ture, the decline in the TBS was much more marked:
-6.2 % in those with osteoporosis-related vertebral frac-
tures grade 2 or greater; -4.6 % in those with an osteo-
porosis-related fracture of any kind; and -7.8 % in those
with 2 or more osteoporosis-related fractures. The age-
adjusted OR for TBS was 1.60 (1.04–2.47) for any osteo-
porosis-related fracture and 1.62 (1.02–2.59) for osteopo-
rosis-related vertebral fractures. In contrast, no significant
association between fracture risk and BMD was found.
Subsequently, Paggiosi et al. [82] assessed the ability of
TBS to discriminate among (a) GC-treated women who
had taken prednisolone C5 mg/day (or the equivalent) for
[3 months (n = 64), (b) women who had sustained a
recent fracture of the distal forearm (n = 46), proximal
humerus (n = 37), vertebra (n = 30) or proximal femur
(n = 28); and (c) healthy women (n = 371). While BMD
and TBS were significantly lower in those with fractures
than in healthy controls, TBS, but not BMD, was signifi-
cantly lower in GC-treated women than in the control
group (p = 0.0004). Although these studies are pre-
liminary and involve a small number of patients, their
results suggest that (1) TBS is reduced in patients on sys-
temic GC treatment compared with normal controls, even
when BMD measured by DXA is similar between the
groups and (2) TBS may aid in the assessment of fracture
risk in such patients.
Cushing’s disease
Endogenous glucocorticoid excess associated with Cush-
ing’s syndrome results in bone loss that may affect tra-
becular bone more than cortical bone. The reduced BMD is
often more pronounced at the lumbar spine, a skeletal site
with a large component of trabecular bone, than at the
femoral neck [83, 84]. Moreover, these patients have an
increased risk for fragility fracture [85]. Several studies
have identified improvement in bone mass in patients with
Cushing’s disease after treatment [84, 86]. One such study
was conducted by Koumakis et al. [87], who examined
treatment effects on BMD and on bone micro-architecture
texture assessed by TBS in 11 patients with Cushing’s
disease (6 women/5 men; mean age 40 years; mean BMI
28 kg/m2, Mean 24-h urinary cortisol before treatment
957 lg/24 h). Ten subjects underwent transsphenoidal
pituitary surgery, while one received medical treatment
alone; all patients experienced normalization of 24-h uri-
nary cortisol with treatment. BMD and TBS increased,
respectively, by 3.7 and 7.3 % after 1 year, and by 7.9 and
13.5 % after 2 years. BMD and TBS were not significantly
correlated with each other before or after treatment. This
was the first study to report bone recovery at the LS both in
BMD and TBS in treated Cushing’s disease.
Adrenal incidentalomas
Adrenal incidentalomas are an uncommon, although
increasingly recognized, cause of subclinical hypercorti-
solism. As with manifestations of exogenous systemic GC
and Cushing’s disease, this excess in cortisol is associated
with an increased risk of fracture, independent of BMD.
Sparse information exists on the effects of these tumors on
bone micro-architecture in humans. Eller-Vainicher et al.
[88] investigated TBS in 102 patients with adrenal inci-
dentaloma and subclinical hypercortisolism diagnosed in
the presence of at least two of the following: (1) urinary
free cortisol [70 mg/24 h (193.1 nmol/L); (2) cortisol
after 1-mg dexamethasone suppression test (1-mg DST)
[3.0 mg/dL (82.8 nmol/L); and (3) adrenocorticotropic
hormone (ACTH)\10 pg/mL (\2.2 pmol/L). In these 102
patients and in 70 matched controls, BMD was measured
by DXA at the LS, femoral neck (FN), and total hip (TH).
The TBS was assessed at the LS. Vertebral deformities
were assessed by plain radiographs. Patients with hyper-
cortisolism (n = 34) had significantly lower LS-BMD
(-0.31 ± 1.17), FN-BMD (-0.29 ± 0.91), and TBS
(-3.18 ± 1.21) than patients without hypercortisolism
(n = 68, 0.31 ± 1.42, 0.19 ± 0.97, and -1.70 ± 1.54) or
controls (0.42 ± 1.52, 0.14 ± 0.76, and -1.19 ± 0.99,
respectively). The presence of a fracture was significantly
associated with a low TBS alone (OR 4.8; 95 %CI
1.85–12.42) and with a pattern of low TBS plus low
LS-BMD (OR 4.37; 95 %CI 1.71–11.4), after adjusting for
age, BMI, and gender. Low TBS plus low LS-BMD
exhibited good specificity (79 %) as a predictor of frac-
tures, whereas normal TBS (i.e., [-1.5) plus normal
LS-BMD was highly specific (88 %) for excluding fractures.
Finally, TBS predicted the occurrence of a new fracture in
40 patients followed for 24 months (OR 11.2; 1.71–71.41;
p \ 0.012) regardless of LS-BMD, BMI, or age.
These findings were echoed by Guglielmi et al. [89],
who measured BMD and TBS in 33 Caucasian Italian
women (mean age 61 years) with adrenal incidentalomas.
Mean values for LS and TH BMD T-scores were -1.49
and -0.65, respectively. Twenty-four percent of the sub-
jects were osteoporotic, 80 % exhibited hypogonadism,
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and 27 % had subclinical hypercortisolism. Compared to
age-matched TBS reference values, TBS was significantly
lower in patients with adrenal incidentaloma, independent
of the LS-BMD T-score classification. Incidentaloma sub-
jects with hypogonadism exhibited a significantly lower
LS-BMD and TBS than incidentaloma subjects without
hypogonadism. In addition, compared to age-matched TBS
reference values, TBS was significantly lower in subjects
with adrenal incidentaloma associated with hypogonadism
and with subclinical hypercortisolism. LS-BMD values in
patients with adrenal incidentaloma and hypogonadism did
not differ from the reference LS-BMD (p [ 0.80). While
this study is limited by the lack of a control group, these
data suggest that bone texture as assessed by TBS is
impaired in subjects with adrenal incidentaloma associate
or not with hypogonadism or subclinical hypercortisolism.
Primary hyperparathyroidism (PHPT)
PHPT is a common endocrinopathy often accompanied by
bone loss readily demonstrated by the evaluation of the
BMD by DXA. In this disease, there is a typical pattern by
DXA, with BMD frequently lowest at the distal 1/3 radius,
a skeletal site that is enriched in cortical bone, and highest
at the LS, a site predominantly comprised of trabecular
bone. Despite the relatively well-preserved trabecular bone
by DXA, recent studies utilizing HRpQCT have shown that
both trabecular and cortical compartments are abnormal in
PHPT [53, 90]. Three independent groups have assessed
TBS in patients with PHPT [91–93] and their results sug-
gest that TBS may identify trabecular abnormalities not
captured by LS-BMD in PHPT [91, 92].
Romagnoli et al. [91] compared 73 Caucasian postmen-
opausal women with PHPT and 74 age- and gender-mat-
ched, healthy controls. In all participants, LS-BMD,
FN-BMD, and TH-BMD were measured by DXA and, in 67
patients and 34 controls, BMD was also measured at the
distal third of the radius (R). TBS was measured in the same
region as LS-BMD. Spinal radiographs were obtained in all
subjects. Mean TBS values were significantly reduced in
PHPT (1.19 ± 0.10) relative to controls (1.24 ± 0.09;
p = 0.01). Patients and controls were not different in age,
years since menopause, BMI, 25(OH)D serum levels, cre-
atinine clearance, LS-BMD, or FN-BMD. BMD at the TH
and 1/3 radius were significantly lower in PHPT patients
than in controls. Within the PHPT group, subjects with
vertebral fractures (n = 29; 24 Grade 1, 4 Grade 2, and 1
Grade 3) had a significantly lower TBS than those without
fractures (n = 44) (1.14 ± 0.10 vs. 1.22 ± 0.10, respec-
tively; p \ 0.01), whose TBS values did not differ from
controls. Mean TBS values in patients with (n = 18) and
without (n = 55) non-vertebral fractures were not signifi-
cantly different (1.16 ± 0.09 vs. 1.20 ± 0.11; p [ 0.05). In
the PHPT group, vertebral fracture was associated with TBS
(AUC: 0.716; 95 %CI 0.590–0.841; p = 0.002), and with
years since menopause (AUC: 0.717; 95 %CI 0.595–0.840;
p = 0.002). The presence of vertebral fractures was not
associated with age, LS-BMD, or BMI. The combination of
‘years since menopause [10’ plus ‘TBS \1.2’ was signifi-
cantly associated with a significant risk of vertebral fracture
(OR = 11.73).
Silva et al. [92] assessed TBS from spine DXA images in
relation to high-resolution peripheral quantitative CT indices
and bone stiffness at the distal radius and tibia in 22 post-
menopausal women with PHPT. In this group, TBS was low
with an average value of 1.240, representing an abnormal tra-
becular pattern (normal [1.35). At the radius, TBS was sig-
nificantly correlated with total (r = 0.49), cortical (Ct;
r = 0.51), and trabecular volumetric BMD (Tb.vBMD;
r = 0.48), cortical thickness (Ct.Th; r = 0.45), Tb.N
(r = 0.51), Tb.Sp (r = -0.49), trabecular heterogeneity
(Tb.Sp SD; r = -0.44), and whole bone stiffness (r = 0.44)
(p\ 0.05 for all associations). Significant correlations
remained after controlling for body weight. At the tibia, TBS
was associated with total (r = 0.62), Ct. (r = 0.47) and
Tb.vBMD (r = 0.53), Ct.Th (r = 0.52), and whole bone
stiffness (r = 0.52) (p \0.05 for all). After adjusting for body
weight, HRpQCT indices of trabecular micro-architecture
were significantly correlated with TBS (Tb.N, r = 0.57;
Tb.Sp, r = -0.52; and Tb.Sp SD, r = -0.48). TBS was not
correlated with total area, Tb.Th and trabecular stiffness at
either site evaluated.
Maury et al. [94] reported on the effects of parathy-
roidectomy, evaluating the longitudinal evolution of spinal
BMD and TBS parameters in 29 postmenopausal Cauca-
sian women (mean age 62 years; mean body mass index
26 kg/m2) with primary hyperparathyroidism (PHPT)
before and 1 year after surgery. Before surgery, all patients
had measurements of serum total and ionized calcium,
phosphate, PTH, and C-telopeptide of type 1 collagen, as
well of 24-h urine calcium and phosphate reabsorption rate.
Before surgery, BMD and TBS were moderately correlated
with each other, TBS explaining 45 % of BMD; neither
BMD nor TBS was correlated with any of the biological
parameters. After surgery, BMD and TBS increased by
4.7 ± 5.4 and 1.6 ± 4 % respectively, with no correlation
between gains in BMD and TBS. Pre-operative total serum
calcium was significantly correlated with BMD gain 1 year
post-surgery. No other correlations were identified between
pre-operative biological parameters and post-treatment
changes in either BMD or TBS. This preliminary study was
the first to report data on changes in spine BMD and TBS,
both assessed by DXA, in women with PHPT undergoing
parathyroid surgery. Consistent with previously-published
data, spine BMD increased after surgery, while TBS
increased more slightly. This last result is consistent with
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what was published when iliac crest biopsies were ana-
lyzed longitudinally post-operatively; i.e., showing
increased trabecular thickness and trabecular spaces.
Eller-Vainicher et al. [93] find that TBS is reduced in
PHPT and associated with vertebral fracture and that it
improves after surgery. In this prospective observational
study, 92 patients with PHPT (74 females, age
62.7 ± 10.1 years) and 98 control subjects were evaluated
at baseline, and in the prospective arm of the study, 20
PHPT subjects who underwent parathyroidectomy were
compared with 10 conservatively treated PHPT patients
after 24 months. Vertebral fractures were assessed by
radiographs. At baseline, PHPT patients had significantly
lower TBS and higher prevalence of vertebral fracture than
controls. BMD was also lower in PHPT than in control
group in all sites measured. TBS was associated with
vertebral fracture (OR 1.4, 95 %CI 1.1–1.9, p = 0.02),
regardless of LS-BMD, age, BMI, and gender. In surgically
treated patients, TBS, LS, TH, and FN-BMD increased
significantly, whereas BMD and TBS seemed to remain
stable in conservatively treated subjects.
Finally, Rolighed et al. [95] evaluated, using a random-
ized double-blind longitudinal study, the role of treatment
with high dose of vitamin D3 in patients with PHPT and a
reduced plasma concentration of 25-hydroxycholecalcifero-
lon the safety and efficacy on calcium homeostasis and bone
metabolism. The evaluation of changes in bone metabolism
included the measurement of bone turnover biochemical
markers, BMD and TBS before and after surgical treatment.
Daily supplementation with 2800 IU cholecalciferol induced
a significant increase in the concentration of 25OHD before
and after PTX (p \ 0.001), as well as a significant reduction
in PTH before PTX (p \ 0.01) in the treated group com-
pared to the placebo group. Likewise, in the treated group,
lumbar spine BMD increased by 2.5 % (p \ 0.01) and CTx
were reduced by 22 % (p \ 0.005) before PTX. After sur-
gical treatment, the spine BMD increased in both groups,
respectively of 2.6 % in treated group and 3.7 % in placebo
group. Before and after PTX, the TBS score of the lumbar
spine was similar in both groups, but when the patients were
considered together, a significant increase in TBS was
observed after PTX. The Authors conclude that the BMD
response to supplementation with vitamin D can not be
identified by TBS. and that ‘‘further studies are needed to
evaluate the changes of an insufficient level of vitamin D on
TBS.’’
Treatment of hormone-receptor positive breast cancer
Bone health is a relevant issue in women undergoing var-
ious hormonal and non-hormonal treatments for breast
cancer, with fractures as common occurrence that signifi-
cantly and adversely affects quality of life and even
survival [96]. Recently, a small substudy of the randomized
Tamoxifen Exemestane Adjuvant Multinational (TEAM)
trial has determined the effects of the aromatase-inhibitor
exemestane and the estrogen-receptor antagonist tamoxifen
on LS-BMD and TBS in postmenopausal women with
hormone-sensitive primary breast cancer [97]. Women
were randomized to receive either tamoxifen (n = 17) or
exemestane (n = 19). Compared to baseline, patients
receiving tamoxifen had a mean increase in LS-BMD of
?1.0 %, ?1.5 %, and ?1.9 %, whereas patients receiving
exemestane showed a mean decline of -2.3, -3.6, and
-5.3 % at 6-, 12-, and 24-month treatment, respectively.
TBS also increased by ?2.2, ?3.5, and ?3.3 % in
tamoxifen-treated subjects, while it decreased by -0.9,
-1.7, and -2.3 % in exemestane-treated women at months
6, 12, and 24, respectively. Changes in TBS from baseline
were different between exemestane and tamoxifen at
months 6 (p \ 0.05), 12 (p \ 0.007), and 24 (p \ 0.006).
No significant correlations were evident between TBS and
BMD for the spine or total hip, either at baseline or during
follow-up
Autoimmune disorders
Several explanations account for the increased bone loss
and fracture risk in subjects with autoimmune disorders,
particularly in those with autoimmune arthritis like rheu-
matoid arthritis, ankylosing spondylitis, and systemic lupus
erythematosus. As already discussed, they often require at
least low-dose systemic corticosteroids early in the course
of illness, while other, slower-acting disease-modifying
treatments are being initiated, and later during disease
flairs. Additional factors that may adversely affect bone
mass and increase fracture risk include reduced physical
exercise, reduced sun exposure leading to low serum levels
of 25-hydroxyvitamin D, and proximal muscle wasting [5].
Patients with rheumatoid arthritis are especially prone to
develop osteoporosis and fragility fractures. In rheumatoid
arthritis and ankylosing spondylitis, bone mass has been
extensively evaluated by measuring areal BMD with DXA;
but few data exist for TBS. Breban et al. [98] studied the
combination of TBS and BMD for vertebral fracture risk
detection in subjects with rheumatoid arthritis with or
without GC treatment. Their study involved 185 women,
mean age 56 ± 14, with rheumatoid arthritis for an average
of 15.5 ± 9.9 years; 112 were receiving GC (mean dose of
6.4 ± 4.3 mg/day), and 162 were on some other disease-
modifying drug. Vertebral fractures from T4 to L4 were
evaluated using vertebral fracture assessment software on
DXA. Vertebral fractures (grade [ 1) were detected in 33
(17.8 %) women. While BMD at the LS and femoral neck
was not different between patients receiving GC and in
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those not taking GC, BMD at the total hip was significantly
lower in patients currently on GC. Similarly, TBS was
lower in patients currently on GC (1.211 ± 0.1161) than in
those not receiving the drug (1.265 ± 0.098; p \ 0.0001).
Despite the low number of fractures, TBS was significantly
lower in patients with vertebral fracture (1.131 ± 0.195)
than in those without fractures (1.245 ± 0.106;
p = 0.0001). The area under the receiver operating char-
acteristic (ROC) curve (AUC) for vertebral fracture risk
prediction was 0.704 for TBS, and 0.621, 0.727, and 0.719
for BMD at the LS, total hip and femoral neck, respec-
tively. A TBS threshold (1.173) was calculated that cor-
responded to the highest levels of sensitivity (75 %) and
specificity (66 %) according to ROC curves for the
detection of vertebral fracture.
In a case–control study, Toussirot et al. [99] evaluated
TBS in patients with rheumatoid arthritis or ankylosing
spondylitis (AS) relative to healthy controls. Changes in LS
and hip BMD and TBS score during anti-tumor necrosis
factor alpha treatment were also prospectively examined.
In the case–control study, 30 patients with rheumatoid
arthritis (American College of Rheumatology criteria, 19
females; 12 postmenopausal women; mean age 57 years;
mean disease duration 12 years; 26 of them on low-dose
corticosteroids) and 30 patients with AS (New York cri-
teria, 27 males, mean age 44 years; mean disease duration
13 years; none on GC) were evaluated and compared to 50
healthy controls. LS-BMD and hip BMD were measured
by DXA. TBS was calculated from L2 to L4 images and
patients with rheumatoid arthritis had significantly lower
BMD and T-scores at the hip than healthy subjects.Patients
with with rheumatoid arthritis (RA) had lower BMD and
T-score at the hip (p \ 0.005) compared to healthy con-
trols. Similarly, Hip T-score in patients with ankylosing
spondylitis (AS) was also decreased (p = 0.02). LS-BMD
did not differ between patients and controls. TBS was
lower in RA and AS compared to controls: 1.242 ± 0.16
and 1.282 ± 0.13 versus 1.365 ± 0.14, respectively
(p = 0.005).In the prospective phase of this study, a group
of 20 patients treated with anti-tumor necrosis factor alpha
(12 ankylosing spondylitis and 8 rheumatoid arthritis) were
followed for 2 years: LS and hip BMD were increased at
24 months (?6.3 and ?2.4 %, respectively), significantly
for the spine. Across the whole group, TBS did not change.
However, in patients with rheumatoid arthritis, TBS sig-
nificantly decreased, while in patients with ankylosin
spondylitis, TBS remained stable. The TBS clearly was
decreased in these two forms of inflammatory rheumatic
disease, especially in rheumatoid arthritis. Long-term anti-
tumor necrosis factor alpha treatment exerted a positive
effect on LS bone mass, but had no influence on TBS.
Contrary to ankylosing spondylitis, the TBS decreased in
rheumatoid arthritis patients treated with anti-tumor
necrosis factor alpha, suggesting that this drug exerts dif-
ferent influences on bone.
Sex steroids
In adult males, both bone mass and levels of gender-related
steroids appear to decline slowly with age. The role of
androgens on the age-related decline in BMD remains
controversial in males. Mascarenhas et al. [100] evaluated
the relationship between testosterone levels and LS TBS,
and BMD at the LS and femoral neck in 80 healthy adult
men (mean age 54 years). Weak but significant correlations
were identified between LS TBS and serum total testos-
terone (r = 0.24; p = 0.03) and the free androgen index
(r = 0.23; p = 0.04). In addition to the clear influence that
female hormones have, total testosterone levels may play a
role in determining bone quality in terms of TBS.
Chronic kidney disease
End-stage renal disease is a well-established risk factor for
reduced BMD and osteoporosis, as well as for hip fracture
[101–103]. The utility of measuring BMD with DXA in
patients with chronic kidney disease remains unclear, since
BMD can be high, low or, normal. Moreover, very limited
data exist concerning the effects of chronic kidney disease
on bone micro-architecture, particularly in the axial skel-
eton. Bone biopsy studies at the iliac crest have demon-
strated micro-structural alterations in both the trabecular
and cortical compartments in these patients. Leib et al.
[104] measured LS TBS in 47 non-Hispanic white women
with chronic kidney disease (mean age 56 years and mean
BMI 26 kg/m2), compared to 94 healthy age- and BMI-
matched women. Twenty-one percent of subjects had
exposure to GC, 3.4 % had thyroid disease, and 17 % had
experienced at least one low-energy fracture. Seventy-three
percent of all subjects were postmenopausal women. The
correlation between spine TBS and BMD was significant
(r = 0.48), whereas spine TBS and BMI were not signifi-
cantly associated (r = 0.08). Subjects with chronic kidney
disease had a significantly lower TBS, whereas spine BMD
was borderline (p = 0.054). Among subjects with chronic
kidney disease, those with a fracture had a significant lower
TBS, whereas no difference was seen for BMD. Also in
subjects with chronic kidney disease, TBS was associated
with the presence of a fracture with an OR per SD decrease
in TBS of 2.5 and AUC of 0.756. Using multivariate
logistic regression via backward selection, chronic kidney
disease was significantly associated with TBS and a
maternal history of hip fracture; meanwhile, BMD, ste-
roids, smoking, and a family history of osteoporosis were
ultimately excluded. The OR per SD decrease in TBS was
4.67 after adjusting for a maternal history of hip fracture.
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Table 1 Summary of a main fully published studies regarding TBS and Secondary Osteoporosis
TBS and secondary osteoporosis
Disease Author Year Study design Patients
no.
Control
no.
Main findings Observation Correlation TBS
versus spine BMD
Hyperparathyroidism
1 Eller-
Vainicher
C
2013 Cross sectional
and
longitudinal
92 98 TBS is associated with VFx (OR
1.4 95 %CI 1.1–1.9). Low TBS
plus low FN-BMD show 71.7 %
of accuracy in detecting pts at
risk of fracture with cut off as
-2,0 for TBS, -0.3 for LS,
-0.2 for TH and -0.6 for FN.
Low TBS and low TBS plus low
FN-BMD show respectively, for
detecting VFxPHPT, SN 75 %;
SP 61.5 %, ACC 67.4 %; SN
52.5 % SP 86.5 % ACC
71.7 %. The surgically treated
pts show a significant Tbs
improvement (-3.03 ± 1,17 vs.
-1.63 ± 0.37), significantly
higher than LS, FN, TH. In
conservatively treated pts with
incident VFx, TBS decreases
respect to pts without, while
BMD changes are not
significant
BMD values of cases and controls
(mean age 62 years) are
expressed as Z-score. TBS data
are reported as Z-score in
relation to the French reference
population
r = 0.27; p = 0.011
2 Romagnoli
E
2013 Cross sectional 73 74 Tbs is reduced in PTHpts and in
those with VF.Tbs \ 1.2 plus
YSM [ 10 show a 11.73 OR
(CI 2.43–66.55). Tbs \ 1.2
shows a negative predictive
value in VF detecting of 81.2
TBS value significantly lower in
patients than in controls
(p \ 0.01)
na
3 Silva BC 2013 Cross sectional 22 0 Tbs correlates with tibia and
radius HRpQCT
(0.23 \ r2 \ 0.38 for radius and
0.23 \ r2 \ 0.44 for Tibia). Tbs
correlates with a BMD third
radius (r = 0.427; p = 0.047)
and UD radius (r = 0.45;
p = 0.036)
r = 0.367; p = NS
4 Rolighed L 2014 Longitudinal 23 23 TBS increased significantly
following PTX in the entire
population (2.8 %, p \ 0.05)
but without significant
differences between w and wo
vitamin D groups
BMD response to vitamin D
supplementation could not be
detected by TBS
na
Diabetes mellitus
1 Leslie WD 2013 Retrospective 2356 27051 LS-Tbs is reduced in DMpts and it
is BMD-independent predictor
of fractures (aHR: 1.27, CI
1.110–1.46). TBS aOR for the
lowest tertile: 2.61, CI 2.3–2.97
while BMD aOR \ 1
All BMD measurements wre
significantly greater in women
with than without diabetes
(p \ 0.001). In contrast, mean
lumbar spine TBS was lower in
the diabetic than non diabetic
women (p \ 0.001)
na
Treatment of hormone-receptor positive breast cancer
1 Kalder M 2013 head to head
(TAM vs.
EXE)
17 19 TBS TAM is lower than TBS
EXE (1273 ± 0.109 vs.
1341 ± 0.084). At 24 mo
versus baseline TBS EXE
-2.3 % ± 1.1 while TBS TAM
3.3 ± 1.6
r = 0.25; p = 0.05
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The investigators concluded that, in the LS, chronic kidney
disease exerts a negative effect on TBS, but no clear effect
on BMD. This study demonstrated, for the first time,
impaired axial trabecular micro-architectural texture in
those with CKD.
Hemochromatosis
Hemochromatosis is a relatively common genetic disease
that causes chronic systemic iron overload. Hemochroma-
tosis creates a state of hyper-intestinal iron absorption.
Homozygous and heterozygous forms exist. In the homo-
zygous form, overload may be massive in various organs
and become life-threatening. The impact of hemochroma-
tosis on bone is known, with osteoporosis identified in
25–34 % of individuals with the homozygous form, with a
controversial impact on trabecular texture. Chapuis et al.
[105]. studied 15 women and 22 men with hemochromatosis
type 1 (mean age and BMI were 56.8 ± 12.6 years and
25.8 ± 4.0 kg/m2 ,respectively). Ferritin and transferrin
saturation were 107.8 ± 90.9 lg/dl and 42.5 ± 12.4 %.
Fifty-seven percent of patients were homozygous, and 11 %
of subjects had a T-score B -2.5 in the spine or femur. A
low, but significant correlation between TBS and L1–L4
BMD was apparent for the entire population (r = 0.41,
p = 0.012). No significant correlations were observed
between iron load, ferritin, and bone parameters. In homo-
zygous patients, a significant positive correlation was noted
between iron load and BMD at any site (0.48\ r \ 0.57,
p \ 0.03) and between iron load and TBS (r = 0.48,
p = 0.028). A significant positive correlation was also
observed between total hip BMD and serum ferritin
(r = 0.50, p = 0.035). In homozygous males, a significant
correlation was apparent between iron load and TBS
(r = 0.800, p \ 0.01), but not between iron load and L1–L4
BMD. No significant differences were observed between
homozygous and heterozygous subjects for iron load or
BMD. However, TBS was significantly lower in
Table 1 continued
TBS and secondary osteoporosis
Disease Author Year Study design Patients
no.
Control
no.
Main findings Observation Correlation TBS
versus spine BMD
Adrenal incidentalomas
1 Eller-
Vainicher
C
2012 Prospective
observational
study
102 (34
wSH;
68
woSH)
70 Low TBS is associated with the
presence of fr (OR 4.8; 95 %CI
1.85–12.42, p = 0.001).The
presence of fr is also associated
with the cluster low TBS plus
low LS-BMD (OR 4.37,
95 %CI 1.71–11.4, p = 0.002).
Low TBS plus LS-BMD show a
good SP (79 %) for predicting
fractures. The combination of
TBS and LS-BMD is useful to
identify pts with and without
SH. The cutoff with the best
compromise between Sn and Sp
is TBS: -1.5 and BMD: -0.0
(Low TBS: SN 81.4 %; Sp
53.5 %, ACC 69.6 %
p \ 0.0001; Low TBS plus low
LS-BMD: Sn 50.8 %, SP
79.1 %, ACC 62.7 %, p 0.002)
BMD values of cases (pts wSH/
woSH) and controls (mean age
67 years) are expressed as
Z-score. TBS data are reported
as Z-score in relation to the
reference population. The
combination of TBS and LS-
BMD is useful to identify pts
wSH and woSH at risk for VF
r = 0.27; p = 0.007
Autoimmune disorders
1 Bre´ban S 2012 cross sectional 185 60 T-scores are significantly lower in
pts with VF than in pts without
VF, difference at femoral neck
(p = 0.0001). Also TBS is
significantly lower in RA pts
with VF than without VF
(1.131 ± 0.195 vs.
1.245 ± 0.106, p = 0.0001).
The threshold of 1.173 for TBS
has the best SN and SP,
respectively 63 % and
74 %).TBS has a better
discrimination value than LS-
BMD for prediction of presence
of VF in pts with RA.
RA woman with VF were
significantly older than those
without VF (p = 0.0004)
r = 0.58, p \ 0.0001
for RA whole pop;
r = 0.52, p = 0.003
for RA wVF;
r = 0.41,
p = 0.0001 for RA
woVF
FN femoral neck BMD, Sn sensitivity, Sp specificity, TAM tamoxifen, EXE exemestane, SH subclinical hypercortisolism, fr fracture, ACC accuracy, w with, wo without, PTX
parathyroidectomy
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heterozygous than in homozygous subjects (p = 0.025).
Based upon these results, TBS could have a role in the
assessment of bone health among hemochromatosis patients,
though further investigations are clearly needed.
Diabetes mellitus
Type 2 diabetes is associated with an increased fracture
risk, but paradoxically greater BMD. Leslie et al. evaluated
the ability of LS TBS to account for increased fracture risk
in diabetics within a large retrospective cohort study con-
ducted in the province of Manitoba, Canada [106]. They
initially screened 29,407 women C50 years with baseline
DXA, among whom 2,356 had diagnosed diabetes. Dia-
betes was associated with higher BMD at all sites, but
lower LS TBS in both unadjusted and adjusted models. The
adjusted OR for measurements in the lowest versus highest
tertile was less than 1.00 for BMD, but was significantly
increased for LS TBS (adjusted OR 2.61). During a mean
follow-up of 4.7 years, major osteoporotic fractures were
identified in 175 women (7.4 %) with diabetes and in 1,493
(5.5 %) without diabetes, with a significant difference
between the groups. LS TBS was a BMD-independent
predictor of fracture, and predicted fractures in those with
diabetes, as well as in those without diabetes (adjusted
hazard ratio 1.27 and 1.31, respectively). The effect of
diabetes on fracture was reduced when LS TBS was added
to a regression model, but was paradoxically increased by
adding BMD measurements. In conclusion, in this one
study, LS TBS was clearly more sensitive than BMD to the
influence of diabetes. LS TBS was able to predict osteo-
porotic fractures in those with diabetes, and captured a
larger portion of the diabetes-associated fracture risk than
BMD.
Conclusions
This article reviewed the potential utility of TBS to eval-
uate the bone texture in individuals with conditions or
diseases related to increased fracture risk (a summary can
be found in Table 1). Data in patients with secondary
osteoporosis, while much less extensive and mostly pub-
lished in abstract form, suggest that TBS may also be
useful for fracture risk assessment in subjects with factors
that predispose to bone loss. In fact, despite the relative
small number of patients evaluated, TBS has been shown to
be associated with fractures in diabetes, primary hyper-
parathyroidism, rheumatoid arthritis, adrenal incidenta-
loma, chronic kidney disease, and in individuals on long-
term GC therapy. Moreover, TBS is reduced in patients
with ankylosing spondylitis, and improves after the
treatment of endocrinological conditions related to reduced
bone mass, such as Cushing’s disease, and primary
hyperparathyroidism. Further research is needed to further
define the promising role of the TBS in these and other
disorders that adversely affect bone.
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